Education and Training
- Fellowship, Gastroenterology, Beth Israel Deaconess Medical Center, 2016 - 2019
- Residency, Internal Medicine, University of California - San Francisco, 2013 - 2016
- M.D., Yale University School of Medicine, 2013
Papamichael, Konstantinos, William T. Clarke, Niels Vande Casteele, Katharine A. Germansky, Joseph D. Feuerstein, Gil Y. Melmed, Corey A. Siegel, Peter M. Irving, and Adam S. Cheifetz. “Comparison of Assays for Therapeutic Monitoring of Infliximab and Adalimumab in Patients With Inflammatory Bowel Diseases.” Clin Gastroenterol Hepatol 19, no. 4 (April 2021): 839-841.e2. https://doi.org/10.1016/j.cgh.2020.03.002.
Clarke, William T., Venkata R. Satyam, David I. Fudman, Samantha Zullow, Kashika G. Goyal, Katerina L. Byanova, Christopher Huang, and Joseph D. Feuerstein. “Antibiotic prophylaxis and infectious complications in patients on peritoneal dialysis undergoing lower gastrointestinal endoscopy.” Gastroenterol Rep (Oxf) 8, no. 5 (October 2020): 407–9. https://doi.org/10.1093/gastro/goaa017.
Papamichael, Konstantinos, Valerio J. Thomas, Andrea Banty, William T. Clarke, Katharine A. Germansky, Sarah N. Flier, Joseph D. Feuerstein, Gil Y. Melmed, and Adam S. Cheifetz. “Clinical Impact of Corrections to Infliximab and Adalimumab Monitoring Results with the Homogeneous Mobility Shift Assay.” J Clin Med 9, no. 9 (September 2, 2020). https://doi.org/10.3390/jcm9092840.
Clarke, William T., Konstantinos Papamichael, Niels Vande Casteele, Katharine A. Germansky, Joseph D. Feuerstein, Gil Y. Melmed, Corey A. Siegel, Peter M. Irving, and Adam S. Cheifetz. “Infliximab and Adalimumab Concentrations May Vary Between the Enzyme-Linked Immunosorbent Assay and the Homogeneous Mobility Shift Assay in Patients With Inflammatory Bowel Disease: A Prospective Cross-Sectional Observational Study.” Inflamm Bowel Dis 25, no. 11 (October 18, 2019): e143–45. https://doi.org/10.1093/ibd/izz202.
Clarke, William T., Janille Miranda, Eitan Neidich, Rebecca Hudock, Marion G. Peters, and Erin M. Kelly. “Metabolic syndrome and liver steatosis occur at lower body mass index in US Asian patients with chronic hepatitis B.” J Viral Hepat 26, no. 10 (October 2019): 1164–69. https://doi.org/10.1111/jvh.13147.
Clarke, William T., Shreya S. Amin, Konstantinos Papamichael, Joseph D. Feuerstein, and Adam S. Cheifetz. “Patients with core antibody positive and surface antigen negative Hepatitis B (anti-HBc+, HBsAg-) on anti-TNF therapy have a low rate of reactivation.” Clin Immunol 191 (June 2018): 59–62. https://doi.org/10.1016/j.clim.2018.03.013.